View of Targeting of both PI3K/Akt/mTOR pathway and mutant EGFR to overcome resistance to tyrosine kinase inhibitors in mutant EGFR-mediated lung cancer

Return to Issue Details Targeting of both PI3K/Akt/mTOR pathway and mutant EGFR to overcome resistance to tyrosine kinase inhibitors in mutant EGFR-mediated lung cancer Download Download PDF